Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Cooperberg

Showing results (201-210 of 522) with videos related to

Pageof 53
Sort By:
Plos One|October 11, 2017
Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)Michael S Leapman, Antonio C Westphalen, Niloufar Ameli, et al.
Urology|February 1, 2003
How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSUREMatthew R Cooperberg, Theresa M Koppie, Deborah P Lubeck, et al.
Prostate Cancer and Prostatic Diseases|September 2, 2018
Practice patterns of primary EBRT with and without ADT in prostate cancer treatmentBogdana Schmidt, Renu S Eapen, Janet E Cowan, et al.
The Prostate|May 12, 2024
Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classificationNancy Y Greenland, Matthew R Cooperberg, Peter R Carroll, et al.
Investigative and Clinical Urology|January 4, 2022
Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancerNancy Y Greenland, Matthew R Cooperberg, Anthony C Wong, et al.
Urologic Oncology|July 19, 2022
Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent DiseaseAvi Baskin, Leslie Bernal Charondo, Ashwin Balakrishnan, et al.
European Urology|October 20, 2023
Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate CancerAnnika Herlemann, Janet E Cowan, Samuel L Washington, et al.
The Journal of Urology|December 2, 2021
Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate CancerPeter E Lonergan, Samuel L Washington, Janet E Cowan, et al.
Urology|May 11, 2005
Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literatureAffonso H L A Camargo, Matthew R Cooperberg, Brent D Ershoff, et al.
BJU International|January 3, 2013
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysisMatthew R Cooperberg, Naren R Ramakrishna, Steven B Duff, et al.
Pageof 53

Showing results (201-210 of 522) with videos related to

Sort By:
Pageof 53
Plos One|October 11, 2017
Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)Michael S Leapman, Antonio C Westphalen, Niloufar Ameli, et al.
Urology|February 1, 2003
How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSUREMatthew R Cooperberg, Theresa M Koppie, Deborah P Lubeck, et al.
Prostate Cancer and Prostatic Diseases|September 2, 2018
Practice patterns of primary EBRT with and without ADT in prostate cancer treatmentBogdana Schmidt, Renu S Eapen, Janet E Cowan, et al.
The Prostate|May 12, 2024
Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classificationNancy Y Greenland, Matthew R Cooperberg, Peter R Carroll, et al.
Investigative and Clinical Urology|January 4, 2022
Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancerNancy Y Greenland, Matthew R Cooperberg, Anthony C Wong, et al.
Urologic Oncology|July 19, 2022
Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent DiseaseAvi Baskin, Leslie Bernal Charondo, Ashwin Balakrishnan, et al.
European Urology|October 20, 2023
Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate CancerAnnika Herlemann, Janet E Cowan, Samuel L Washington, et al.
The Journal of Urology|December 2, 2021
Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate CancerPeter E Lonergan, Samuel L Washington, Janet E Cowan, et al.
Urology|May 11, 2005
Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literatureAffonso H L A Camargo, Matthew R Cooperberg, Brent D Ershoff, et al.
BJU International|January 3, 2013
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysisMatthew R Cooperberg, Naren R Ramakrishna, Steven B Duff, et al.
Pageof 53